You are here:

Archived: Pegvisomant (Somavert)


Following a re-submission.

Pegvisomant (Somavert®) is not recommended for use within NHS Scotland for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise insulin-like growth factor 1 (IGF-1) concentrations or was not tolerated. Pegvisomant reduces IGF-1 levels significantly and improves some of the clinical manifestations of acromegaly. It is acknowledged that this is an orphan drug but the economic case has not been demonstrated.

Drug Details

Drug Name: Pegvisomant (Somavert)
SMC Drug ID: 158/05
Manufacturer: Pfizer Ltd
Indication: Acromegaly
BNF Category:
Sub Category: 6.5 Hypothalamic and pituitary hormones and anti-oestrogens
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 5 May 2006

Current Advice

Resubmission 13 November 2017

Archived Advice

Full submission 9 May 2005